O. Yeku, D. Olson, J. Ward, S. Patel, J. Aycock, Amber C. Donahue, Yi-zhou Jiang, J. Gall, Z. Roberts, Rubén Álvarez-Rodríguez, Judy Seng, Tong Shen, N. Kothari
{"title":"781 DELTA-2:一项i期、开放标签、多中心研究,itl -168是一种自体肿瘤浸润性淋巴细胞(TIL)细胞疗法,联合派姆单抗治疗晚期实体瘤患者","authors":"O. Yeku, D. Olson, J. Ward, S. Patel, J. Aycock, Amber C. Donahue, Yi-zhou Jiang, J. Gall, Z. Roberts, Rubén Álvarez-Rodríguez, Judy Seng, Tong Shen, N. Kothari","doi":"10.1136/jitc-2022-sitc2022.0781","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":398566,"journal":{"name":"Regular and Young Investigator Award Abstracts","volume":"23 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"781 DELTA-2: A phase 1, open-label, multicenter study of ITIL-168, an autologous tumor-infiltrating lymphocyte (TIL) cell therapy, with pembrolizumab in patients with advanced solid tumors\",\"authors\":\"O. Yeku, D. Olson, J. Ward, S. Patel, J. Aycock, Amber C. Donahue, Yi-zhou Jiang, J. Gall, Z. Roberts, Rubén Álvarez-Rodríguez, Judy Seng, Tong Shen, N. Kothari\",\"doi\":\"10.1136/jitc-2022-sitc2022.0781\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":398566,\"journal\":{\"name\":\"Regular and Young Investigator Award Abstracts\",\"volume\":\"23 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Regular and Young Investigator Award Abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/jitc-2022-sitc2022.0781\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Regular and Young Investigator Award Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/jitc-2022-sitc2022.0781","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
781 DELTA-2: A phase 1, open-label, multicenter study of ITIL-168, an autologous tumor-infiltrating lymphocyte (TIL) cell therapy, with pembrolizumab in patients with advanced solid tumors